All Stories

  1. Chemoprevention acceptance and adherence in women with high-risk breast lesions
  2. Lumpectomy specimen margins are not reliable in predicting residual disease in breast conserving surgery
  3. Can older women with early breast cancer avoid radiation?
  4. Reply to A.S. Sie et al, K. Hemminki et al, and J. Larsen Haidle
  5. Template for Reporting Results of Biomarker Testing of Specimens From Patients With Carcinoma of the Breast
  6. Surgical excision of radial scars diagnosed by core biopsy may help predict future risk of breast cancer
  7. American Society of Clinical Oncology Expert Statement: Collection and Use of a Cancer Family History for Oncology Providers
  8. Quality of Cancer Family History and Referral for Genetic Counseling and Testing Among Oncology Practices: A Pilot Test of Quality Measures As Part of the American Society of Clinical Oncology Quality Oncology Practice Initiative
  9. Implementation of an electronic genomic and family health history tool in primary prenatal care
  10. Clinical Decision Support for Personalized Medicine
  11. Reply to P.G. Tsoutsou et al, O. Kaidar-Person et al, and A. Courdi et al
  12. Evaluation of a Novel Electronic Genetic Screening and Clinical Decision Support Tool in Prenatal Clinical Settings
  13. Lumpectomy Plus Tamoxifen With or Without Irradiation in Women Age 70 Years or Older With Early Breast Cancer: Long-Term Follow-Up of CALGB 9343
  14. Providing access to risk prediction tools via the HL7 XML-formatted risk web service
  15. Simplifying clinical use of the genetic risk prediction model BRCAPRO
  16. Personalizing prenatal care using family health history: identifying a panel of conditions for a novel electronic genetic screening tool
  17. The High-Tech High Risk Clinic
  18. The role of chemoprevention in modifying the risk of breast cancer in women with atypical breast lesions
  19. Which Risk Model to Use? Clinical Implications of the ACS MRI Screening Guidelines
  20. Application of ACOSOG Z0011 Criteria Reduces Perioperative Costs
  21. Sentinel lymph node biopsy at the time of mastectomy does not increase the risk of lymphedema: implications for prophylactic surgery
  22. Cost Comparison of Radiation Treatment Options After Lumpectomy for Breast Cancer
  23. Adjuvant Therapy in Stage I Carcinoma of the Breast: The Influence of Multigene Analyses and Molecular Phenotyping
  24. Aromatase inhibition to decrease background parenchymal enhancement
  25. Hereditary Breast and Ovarian Cancer and Other Hereditary Syndromes: Using Technology to Identify Carriers
  26. Managing Patients at High Risk for Hereditary Breast Cancer: A Guide for the Practicing Physician
  27. Long-term follow-up of Jewish women with a BRCA1 and BRCA2 mutation who underwent population genetic screening
  28. Bias in the Reporting of Family History: Implications for Clinical Care
  29. Determinants of outcome in elderly patients with positive sentinel lymph nodes
  30. Lumpectomy Cavity Shaved Margins Do Not Impact Re-excision Rates in Breast Cancer Patients
  31. The complexity of breast cancer risk needs to be embraced, not oversimplified
  32. The Safety of Multiple Re-excisions after Lumpectomy for Breast Cancer
  33. Oncology Lifeline - A Timeline Tool for the Interdisciplinary Management of Breast Cancer Patients in a Surgical Clinic
  34. The Potential of the Electronic Health Record in the Breast Center
  35. Diagnosis of breast cancer in women age 40 and younger: delays in diagnosis result from underuse of genetic testing and breast imaging
  36. Outcome of multiple-wire localization for larger breast cancers: do multiple wires translate into additional imaging, biopsies, and recurrences?
  37. Identification and Management of Women at High Risk for Hereditary Breast/Ovarian Cancer Syndrome
  38. Proceedings of the International Consensus Conference on Breast Cancer Risk, Genetics, & Risk Management, April, 2007
  39. Breast Cancer After Treatment of Hodgkin's Lymphoma: Risk Factors That Really Matter
  40. Challenges and Improvements in the Identification of Women at High Risk
  41. Clinical outcome of breast cancer occurring after treatment for Hodgkin's lymphoma: case-control analysis
  42. The American Cancer Society guidelines for breast screening with magnetic resonance imaging
  43. Proceedings of the International Consensus Conference on Breast Cancer Risk, Genetics, & Risk Management, April, 2007
  44. Do sentinel node micrometastases predict recurrence risk in ductal carcinoma in situ and ductal carcinoma in situ with microinvasion?
  45. Outcomes of Multiple Wire Localization for Larger Breast Cancers: When Can Mastectomy Be Avoided?
  46. Consensus Conference on Breast Conservation
  47. Management and Outcome of Ipsilateral Recurrence Following Breast Conservation
  48. Sentinel Node Biopsy is Important in Mastectomy for Ductal Carcinoma In Situ
  49. Detecting Occult Malignancy in Prophylactic Mastectomy: Preoperative MRI Versus Sentinel Lymph Node Biopsy
  50. Accuracy of Self-Reported Personal History of Cancer in an Outpatient Breast Center
  51. Mammographic Breast Density and Race
  52. Elastic stay hooks and self-retaining retractor technique for mastectomy skin flaps
  53. The use of radiation in the elderly
  54. Accelerated partial-breast irradiation using proton beams: Initial clinical experience
  55. Consensus Conference on Breast Conservation
  56. Breast Cancer Diagnosis in Women ≤ 40 versus 50 to 60 Years: Increasing Size and Stage Disparity Compared With Older Women Over Time
  57. Initial dosimetric experience using simple three-dimensional conformal external-beam accelerated partial-breast irradiation
  58. Proceedings of the consensus conference on breast conservation, April 28 to May 1, 2005, Milan, Italy
  59. Prevalence of hereditary breast/ovarian carcinoma risk in patients with a personal history of breast or ovarian carcinoma in a mammography population
  60. A comparison of sentinel node biopsy before and after neoadjuvant chemotherapy: timing is important
  61. Family History Information Exchange Services Using HL7 Clinical Genomics Standard Specifications
  62. Palpable right breast mass in a pregnant woman
  63. 1–52 The Relationship Among Physicians' Specialty, Perceptions of the Risks and Benefits of Adjuvant Tamoxifen Therapy, and Its Recommendation in Older Patients With Breast Cancer
  64. Breast cancer treatment in older women
  65. Lumpectomy plus tamoxifen with or without irradiation in women 70 years of age or older with early breast cancer
  66. The age at which women begin mammographic screening
  67. Lumpectomy plus Tamoxifen with or without Irradiation in Women 70 Years of Age or Older with Early Breast Cancer
  68. Mammographic screening: Patterns of use and estimated impact on breast carcinoma survival
  69. Gauging the impact of breast carcinoma screening in terms of tumor size and death rate
  70. The effect of tumor size and lymph node status on breast carcinoma lethality
  71. Racial differences in mammographic breast density
  72. A simple model of breast carcinoma growth may provide explanations for observations of apparently complex phenomena
  73. Estimates of the Sizes at Which Breast Cancers Become Detectable on Mammographic and Clinical Grounds
  74. Prevalence of Family History of Breast and Ovarian Cancer in a Single Primary Care Practice Using a Self-Administered Questionnaire
  75. Predicting the survival of patients with breast carcinoma using tumor size
  76. BRCAPRO Validation, Sensitivity of Genetic Testing ofBRCA1/BRCA2, and Prevalence of Other Breast Cancer Susceptibility Genes
  77. Disparate E-cadherin mutations in LCIS and associated invasive breast carcinomas
  78. The Effectiveness of the Gail Model in Estimating Risk for Development of Breast Cancer in Women Under 40 Years of Age
  79. Use of Carcinoembryonic Antigen Radioimmunodetection and Computed Tomography for Predicting the Resectability of Recurrent Colorectal Cancer
  80. Lymph node negative invasive breast carcinoma 1 centimeter or less in size (T1a,bN0M0)
  81. Guest editorial: How do we apply genetic testing for breast cancer susceptibility to clinical practice?
  82. CONTROVERSIES IN THE TREATMENT OF DUCTAL CARCINOMA IN SITU
  83. Male breast carcinoma: An evaluation of prognostic factors contributing to a poorer outcome
  84. Ductal carcinoma in situ of the male breast
  85. The Role of Axillary Dissection in Early Stage Breast Cancer
  86. Morbidity and mortality of hepatic resection for metastatic colorectal carcinoma
  87. Intra-abdominal extrahepatic disease in patients with colorectal hepatic metastases
  88. Resection of the liver for colorectal carcinoma metastases
  89. Family History Information Exchange Services Using HL7 Clinical Genomics Standard Specifications